Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study.

Abstract

BACKGROUND:

The Veterans Affairs Cooperative Studies Program study #553 was designed to evaluate the efficacy of adjuvant chemotherapy added to the standard of care (SOC) for patients who are at high risk for relapse after prostatectomy.

OBJECTIVE:

To test whether addition of chemotherapy to surgery for high-risk prostate cancer improves progression-free survival (PFS).

DESIGN, SETTING, AND PARTICIPANTS:

Eligible patients after prostatectomy were randomized to the SOC group with observation or to the chemotherapy group with docetaxel and prednisone administered every 3 wk for six cycles. Randomization was stratified for prostate-specific antigen, Gleason, tumor stage, and surgical margin status.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:

The primary endpoint was PFS. Secondary endpoints included overall, prostate cancer-specific, and metastasis-free survival, and time to androgen deprivation therapy.

RESULTS AND LIMITATIONS:

A total of 298 of the planned 636 patients were randomized. The median follow-up was 59.1 mo (0.2-103.7 mo). For the primary endpoint, the two groups did not statistically differ in PFS (median 55.5 mo in the chemotherapy group and 42.2 mo in the SOC group; test adjusted for site via gamma frailty p=0.21; adjusted hazard ratio [HR] 0.80; 95% confidence interval [CI] 0.58-1.11; p=0.18). Prespecified subgroup analyses showed benefit in PFS for patients with tumor stage ≥T3b (HR 0.54, 95% CI 0.32-0.92; p=0.022) and patients with Gleason score ≤7 (HR 0.65, 95% CI 0.43-0.99; p=0.046). Secondary endpoint analyses are hampered by low event rates. The most common adverse events (≥grade 3 related or possibly related to chemotherapy) included neutropenia (43%), hyperglycemia (20%), and fatigue (5%), with febrile neutropenia in 2%.

CONCLUSIONS:

Adjuvant chemotherapy in high-risk prostate cancer using docetaxel and prednisone did not lead to statistically significant improvement in PFS for the intention-to-treat population as a whole. The analysis was challenged by lower power due to accrual limitation. Subgroup analyses suggest potential benefit for patients with Gleason grade ≤7 and stage≥pT3b (ClinicalTrials.gov number NCT00132301).

PATIENT SUMMARY:

In this randomized trial, we tested whether addition of chemotherapy to surgery for high-risk prostate cancer decreased the risk of prostate-specific antigen rise after surgery. We found no benefit from docetaxel given after radical prostatectomy, although some subgroups of patients may benefit.

• Authors: Daniel W Lin, Mei-Chiung Shih, William Aronson, Joseph Basler, Tomasz M Beer, Mary Brophy, Matthew Cooperberg, Mark Garzotto, W Kevin Kelly, Kelvin Lee, Valerie McGuire, Yajie Wang, Ying Lu, Vivian Markle, Unyime Nseyo, Robert Ringer, Stephen J Savage, Patricia Sinnott, Edward Uchio, Claire C Yang, R Bruce Montgomery
• Journal: European urology (Eur Urol) Vol. 77 Issue 5 Pg. 563-572 (05 2020) ISSN: 1873-7560 [Electronic] Switzerland
• PMID: 31924316 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, Non-P.H.S.)
• Copyright: Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Topics

• Aged
• Aged, 80 and over
• Chemotherapy, Adjuvant
• Humans
• Male
• Middle Aged
• Progression-Free Survival
• Prostatectomy
• Prostatic Neoplasms (drug therapy, surgery)
• Risk Assessment
• United States
• United States Department of Veterans Affairs